• Home
  • Research
  • Duke-NUS partners with Arcturus Therapeutics to develop COVID-19 vaccine

Duke-NUS partners with Arcturus Therapeutics to develop COVID-19 vaccine

05 March 2020 | Research - Impact

Duke-NUS and Arcturus Therapeutics, a leading messenger RNA medicines company, have announced their partnership to develop a COVID-19 vaccine for Singapore. The vaccine will take advantage of the unique platform developed at Duke-NUS which allows rapid screening of vaccines for effectiveness and safety



  • Home
  • Research
  • Duke-NUS partners with Arcturus Therapeutics to develop COVID-19 vaccine